MorphoSys issued patent for HuCAL antibody library.
"The HuCAL patent family sits at the core of our technologies and the grant of this patent significantly strengthens our patent portfolio. Moreover, the speed in which the United States patent office granted our patent application points to the clear and undisputed novelty and inventiveness of the HuCAL technology," commented Dr. Thomas von Rueden, Chief Scientific Officer of MorphoSys AG.
Recently another patent was granted to MorphoSys in the United States (US 6,294,353), entitled "Targeted hetero-association of recombinant proteins to multi-functional complexes", further strengthening MorphoSys' intellectual property portfolio. The patent covers multifunctional protein complexes formed by certain hetero-associating domains.
To-date, MorphoSys has four patents granted and more than 40 applications pending worldwide. The patents and pending applications cover a variety of different technologies, including antibody libraries, screening methods such as the EST and CysDisplay technologies, certain antibody fragment formats, and specific antibodies.
MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the company's proprietary Human Combinatorial Antibody Library (HuCAL) technology is used by researchers worldwide for human antibody generation. The company currently has licensing and research collaborations with Bayer AG (Berkeley, California/USA), Biogen Inc. (Cambridge, Massachusetts/USA), Centocor Inc. (Malvern, Pennsylvania/USA), DuPont Pharmaceuticals Inc. (Wilmington, Delaware/USA), Eos Biotechnology Inc. (San Francisco, California/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Millennium Inc. (Cambridge, Mass/USA), Oridis Biomed GmbH (Graz/Austria) and ProChon Biotech Ltd. (Rehovot/Israel).
|Printer friendly Cite/link Email Feedback|
|Comment:||MorphoSys issued patent for HuCAL antibody library.|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||Oct 1, 2001|
|Previous Article:||NeoTherapeutics receives patent for serotonin-like hypoxanthines.|
|Next Article:||Harvard Bioscience receives 'notice of allowability' for organism sorting technology.|